Review on clinical trials of targeted treatments in malignant mesothelioma (Q37873380)

24 August 2017

1 reference

title

Review on clinical trials of targeted treatments in malignant mesothelioma (English)

1 reference

24 August 2017

Jan Nyrop Jakobsen

1

1 reference

24 August 2017

Jens Benn Sørensen

series ordinal

2

1 reference

24 August 2017

publication date

7 May 2011

1 reference

Cancer Chemotherapy and Pharmacology

24 August 2017

published in

1 reference

24 August 2017

volume

68

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

1-15

1 reference

Malignant mesothelioma in south east England: clinicopathological experience of 272 cases

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

New agents in the management of advanced mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Second-line treatment for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Angiogenesis is an independent prognostic factor in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Serum PDGF-AB in pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Predictors of competing mortality in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Antiangiogenic therapies for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Thalidomide in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Cellular and molecular parameters of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Stopping clinical trials by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1655-3

10.1007/S00280-011-1655-3

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference